PT001 MDI Versus Atrovent Study in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Completed · Phase 2 · Has a placebo group

Conditions studied: Chronic Obstructive Pulmonary Disease

In brief

The overall objective of this study is to determine an optimal dose and dosing regimen of PT001 MDI for further evaluation in later stage studies.

Key facts

Study ID

NCT01350128

Run by

Pearl Therapeutics, Inc.

People needed

103

Starts

2011-05-01

Expected to finish

2011-10-01

Last updated by the study team

2018-06-20

Who can join

Age: 40 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Pearl Investigative Site — Panama City, Florida, United States
• Pearl Investigative Site — Winter Park, Florida, United States
• Pearl Investigative Site — Cherry Hill, New Jersey, United States
• Pearl Investigative Site — Summit, New Jersey, United States
• Pearl Investigative Site — Charlotte, North Carolina, United States
• Pearl Investigative Site — Medford, Oregon, United States
• Pearl Investigative Site — Longview, Texas, United States
• Pearl Investigative Site — Richmond, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.